Beijing Konruns PharmaceuticalLtd Valuation
Is 603590 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 603590 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von 603590 für die Bewertungsanalyse.
Deutlich unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von 603590 für die Bewertungsanalyse.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 603590?
Other financial metrics that can be useful for relative valuation.
| What is 603590's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CN¥4.92b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.7x |
| Enterprise Value/EBITDA | 20.2x |
| PEG Ratio | 1.7x |
Price to Earnings Ratio vs Peers
How does 603590's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 16.4x | ||
600351 Yabao Pharmaceutical Group | 22.8x | n/a | CN¥4.8b |
600479 ZhuZhou QianJin PharmaceuticalLtd | 14.9x | n/a | CN¥4.8b |
002393 Tianjin Lisheng PharmaceuticalLtd | 12.8x | n/a | CN¥4.6b |
300194 Fuan Pharmaceutical (Group) | 15x | n/a | CN¥4.8b |
603590 Beijing Konruns PharmaceuticalLtd | 33.6x | 19.7% | CN¥4.9b |
Price-To-Earnings gegen Gleichaltrige: 603590 ist auf der Grundlage des Price-To-Earnings Verhältnisses (43.1x) im Vergleich zum Durchschnitt der Vergleichsgruppe (22.9x) teuer.
Price to Earnings Ratio vs Industry
How does 603590's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?
Price-To-Earnings gegen Industrie: 603590 ist teuer, wenn man sein Price-To-Earnings Verhältnis (31.5x) mit dem CN Pharmaceuticals Branchendurchschnitt (25.4x) vergleicht.
Price to Earnings Ratio vs Fair Ratio
What is 603590's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 33.6x |
| Fair PE Ratio | 22.1x |
PM vs. Fair Ratio: 603590 ist teuer auf der Grundlage des Verhältnisses Price-To-Earnings (31.5x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Earnings (21x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.